Millennium Pharmaceuticals, Inc. Sustainability Profile
Millennium Pharmaceuticals, Inc., a subsidiary of Takeda Pharmaceutical Company, is a prominent player in the biotechnology industry, headquartered in the United States. Founded in 1993, the company has made significant strides in oncology, focusing on innovative therapies for cancer treatment. With a strong presence in North America and Europe, Millennium is renowned for its commitment to advancing cancer care through cutting-edge research and development. The company’s flagship products, including Velcade and Ninlaro, are distinguished by their unique mechanisms of action, offering new hope to patients with multiple myeloma and other malignancies. Millennium's dedication to scientific excellence has positioned it as a leader in the oncology market, with numerous accolades recognising its contributions to cancer therapeutics. Through its ongoing efforts, Millennium Pharmaceuticals continues to shape the future of cancer treatment, striving to improve patient outcomes worldwide.
DitchCarbon Score
How does Millennium Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Millennium Pharmaceuticals, Inc.'s score of 72 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Millennium Pharmaceuticals, Inc., headquartered in the US, currently does not report specific carbon emissions data, as no figures are available. However, the company is a current subsidiary of Takeda Pharmaceutical Company Limited, which influences its climate commitments and initiatives. Millennium Pharmaceuticals inherits its climate-related targets and performance metrics from Takeda Pharmaceutical Company Limited. This includes commitments to the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP), both of which are aimed at reducing greenhouse gas emissions across their operations. The specific reduction targets and achievements of Takeda, which cascade down to Millennium, are not detailed in the available data. As part of its corporate family, Millennium Pharmaceuticals aligns with Takeda's broader sustainability goals, which focus on reducing emissions across all scopes, including Scope 1, 2, and 3. While specific numbers are not provided, the overarching commitment to climate action reflects a dedication to addressing environmental impacts within the pharmaceutical industry. In summary, while Millennium Pharmaceuticals, Inc. does not have specific emissions data or reduction targets available, it is guided by the climate initiatives and performance metrics of its parent company, Takeda Pharmaceutical Company Limited.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 96,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 161,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 |
| Scope 3 | 226,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Millennium Pharmaceuticals, Inc.'s Industry?
How Carbon Intensive is Millennium Pharmaceuticals, Inc.'s Location?
Millennium Pharmaceuticals, Inc.'s Scope 3 Categories Breakdown
Millennium Pharmaceuticals, Inc.'s Scope 3 emissions, which decreased by 23% last year and increased significantly since 2015, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 68% of Scope 3 emissions.
Top Scope 3 Categories
Millennium Pharmaceuticals, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Millennium Pharmaceuticals, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
